Funding for this research was provided by:
Biogen
Article History
Received: 2 February 2021
Revised: 14 June 2021
Accepted: 16 June 2021
First Online: 2 August 2021
Declarations
:
: GP: speaker honoraria and/or consulting fees from Alexion, Biogen, Celgene, EMD Serono, Greenwich Pharmaceuticals, Novartis, Roche/Genentech, and Sanofi-Genzyme, and research support (to the institution) from AbbVie, Adamas, Alkermes, Biogen, EMD Serono, Roche/Genentech, Sanofi Genzyme, Novartis, and Teva; SC: funding for research and draft development from Biogen; DTO: personal compensation for consulting and advisory services from Alexion, Biogen, Celgene, Genzyme, EMD Serono, and TG Therapeutics, VielaBio and research support from Biogen and EMD Serono.